Posts tagged CLVS


Company Update (NASDAQ:CLVS): Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet

Clovis Oncology Inc (NASDAQ:CLVS) announced that comprehensive data from the Phase 3 ARIEL3 study of …

Read more

Clovis Oncology Inc (CLVS): Is the Pullback a Buying Opportunity?

J.P. Morgan dismantles investor concerns of liver toxicity, patient deaths, and “underwhelming” combo data.

Read more

Clovis Oncology Inc (CLVS) PARP Product Will Not Be Hit by AstraZeneca’s FDA Approval: J.P. Morgan

The FDA approved this morning a new indication for AstraZeneca’s (NYSE:AZN) ARP inhibitor Lynparza. The …

Read more

Clovis Oncology Inc (CLVS) and Bristol-Myers Squibb (BMY) Enter Into Clinical Collaboration Agreement

Clovis Oncology Inc (NASDAQ:CLVS) and Bristol-Myers Squibb Co (NYSE:BMY) announced the companies have entered into a …

Read more

Stock Update (NASDAQ:CLVS): Clovis Oncology Inc Announces Proposed Offering of Common Stock

Clovis Oncology Inc (NASDAQ:CLVS) announced that it has commenced an underwritten public offering of shares …

Read more

Analysts Weigh in on Two Skyrocketing Stocks: Novadaq Technologies Inc. (NVDQ), Clovis Oncology Inc (CLVS)

Novadaq Technologies Inc. Novadaq Technologies Inc. (NASDAQ:NVDQ) shares are skyrocketing 95% to $11.70, following the …

Read more

J.P. Morgan Boosts Price Target for Clovis Oncology Inc (CLVS) on Back of Additional Pipeline Value

J.P. Morgan analyst Cory Kasimov is out with a new research report on shares of Neutral-rated Clovis …

Read more

Stock Update (NASDAQ:CLVS): Clovis Oncology Inc Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

Clovis Oncology Inc (NASDAQ:CLVS) announced that the underwriters of its recently announced public offering of …

Read more

Stock Update (NASDAQ:CLVS): Clovis Oncology Inc Announces Proposed Offering of Common Stock to Raise $175 Million

Clovis Oncology Inc (NASDAQ:CLVS) announced that it has commenced an underwritten public offering of shares …

Read more

Piper Jaffray Raises Price Target on Clovis Oncology Inc (CLVS); Believes 2017 Will Be Defining

Piper Jaffray analyst Steven Breazzano remains sidelined, but optimistic on Clovis Oncology Inc (NASDAQ:CLVS) following …

Read more